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Distribution of pathogens 
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Changing microorganism distributions and decreasing antibiotic susceptibility over the duration of 
hospitalization have been described for the colonization or infection of selected organ systems. Few 
data are available on bacteremias in the intensive care unit (ICU) setting. We conducted a nationwide 
study on bloodstream infection (BSI) using data from  the Swiss Centre for Antibiotic Resistance 
(ANRESIS). We analyzed data on BSI detected in the ICU from hospitals that sent information on a 
regular basis during the entire study period (2008–2017). We described specific trends of pathogen 
distribution and resistance during hospitalization duration. We included 6505 ICU‑ BSI isolates from 35 
Swiss hospitals. We observed 2587 possible skin contaminants, 3788 bacteremias and 130 fungemias. 
The most common microorganism was Escherichia coli (23.2%, 910), followed by Staphylococcus 
aureus (18.7%, 734) and enterococci (13.1%, 515). Enterococcus spp (p < 0.0001) and Candida spp 
(p < 0.0001) increased in proportion, whereas E. coli (p < 0.0001) and S. aureus (p < 0.0001) proportions 
decreased during hospitalization. Resistances against first‑ and second‑line antibiotics increased 
linearly during hospitalization. Pathogen distribution and antimicrobial resistance in ICU‑BSI depends 
on the duration of the hospitalization. The proportion of enterococcal BSI, candidemia and resistant 
microorganisms against first‑ and second‑line antibiotics increased during hospitalization.
Intensive care unit acquired bloodstream infection (ICU-BSI) is a common healthcare-associated infection and 
is associated with high  mortality1–3. Little is known on the relationship between the hospitalization duration 
and the epidemiology of ICU-BSI. Decreasing antibiotic susceptibility with increasing length of hospital stay 
has previously been illustrated for the infection of selected organ  systems4–6. To our knowledge, the length of 
hospital stay and its impact on the ICU-BSI epidemiology was never specifically assessed in a large multi-centric 
cohort. Only few authors have investigated this question for bacteremia in the non-ICU  setting7,8. Our objective 
was to describe distribution of pathogens and antimicrobial resistance in ICU-BSI according to the duration of 
hospitalization using a large national microbiological database.
Material and methods
Design and data collection. We conducted a nationwide, observational study on BSI using data from the 
Swiss Centre for Antibiotic Resistance (ANRESIS) data from 1st January 2008 to 31st December 2017. ANRESIS 
regularly receives information on all positive blood cultures from 30 Swiss microbiology laboratories, some of 
them collecting data from several  hospitals8. Hospitals are distributed across the country and representing at 
least 80% of annual hospitalization  days9. Accordingly, we analyzed data of BSIs from those Swiss hospitals that 
sent information on a regular basis (i.e., without major fluctuations in reporting) during the entire study period. 
Only isolates sampled in the ICU from Swiss hospitals sending information on hospital length of stay at time of 
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sampling were included. In order to remove any bias introduced by an individual patient’s resistance evolution, 
only the first isolate of a species per patient was eligible for this analysis: duplicates (i.e., the same microorganism 
identified in subsequently collected blood samples) were excluded. Moreover, we restricted the dataset to patho-
gens that occurred > 10 times during the study period (i.e., belonging to predominant and/or relevant species). 
We used the term “bloodstream infection” (BSI) instead of “bacteremia and fungemia” throughout the  text10.
Microbiological data and resistance. Species identification and antimicrobial susceptibility testing 
are performed in local laboratories according to European Committee on Antimicrobial Susceptibility Testing 
(EUCAST, https:// eucast. org) or Clinical and Laboratory Standards Institute (CLSI, https:// clsi. org) guidelines. 
All laboratories are participating in at least one external quality program of either the Swiss quality control pro-
gram issued by the Institute for Medical Microbiology, University of Zürich (http:// www. imm. uzh. ch/ servi ces/ 
qc. html), or the National External Quality Assessment Service (NEQAS; www. ukneg as. org. uk).
Resistant isolates were defined as those who were resistant or displayed intermediate susceptibility against 
the antibiotic tested. Resistance against first-line antibiotics was defined as resistance against amoxicillin for 
enterococci, ceftriaxone and/or amoxicillin/clavulanic acid for Gram-negative microorganisms and oxacillin 
for Staphylococcus aureus8. All non-fermenting Gram-negative bacteria were considered as resistant to first-line 
antibiotics as detailed above. Resistance against second-line antibiotics was defined as vancomycin resistance for 
Gram-positive and carbapenem resistance for Gram-negative microorganisms. Fungal pathogens were classified 
as resistant to first and second line antibacterials.
We regarded coagulase-negative Staphylococci, Corynebacterium sp, Micrococcus spp and Cutibacterium acnes 
as possible skin contaminants and analyzed them separately. Staphylococcus lugdunensis was not included.
Variables collected. Epidemiological data allowed stratification by age group, sex, hospital type (commu-
nity versus university), and year of detection. “Early hospital-acquired” was defined as BSI between 2 and 5 days 
after hospitalization, whereas “late hospital-acquired” BSI were those occurring > 5 days after hospitalization. 
The remaining BSIs were labeled as community-acquired. The duration of hospitalization was calculated using 
hospital admission date and BSI date. ICU admission date was not available.
Statistical analysis. The analytical plan had two steps: (1) to describe characteristics of BSI in different hos-
pital acquisition scenarios (i.e., community versus early hospital-acquired versus late hospital-acquired); (2) to 
describe trends in pathogen distribution and resistance during the hospitalization using graphical descriptions 
and descriptive statistics. Characteristics depending on the hospitalization duration were compared with chi-
square or Fisher test, as appropriate. The prevalence of a specific microorganism was calculated as the number 
of this microorganism over the total number of isolates. The prevalence of resistance (i.e., against first or second 
line antibiotics) was calculated as the number of resistant strains over the total number of this isolate. Changes in 
the prevalence during the hospitalization were assessed using the Cochrane–Armitage test. A sensitivity analysis 
excluding fungi was added. The data analysis for this paper was generated using (1) SAS software, version 9.4 
(SAS Institute, Inc., Cary, NC), and (2) R version 3.6.1 (R Core Team (2020). R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:// www.R- proje ct. org/). p 
values < 0.05 were considered to be statistically significant. As the analysis was performed on anonymized non-
genetic surveillance data, ethical consent was not required according to the Swiss law for research on humans.
Results
From 2008 to 2017, we included data on 6505 ICU-BSIs from 35 Swiss hospitals (Figs. 1, 2). Possible skin con-
taminants were 2587.
After excluding possible skin contaminants, we observed 3788 bacteremias and 130 fungemias. BSIs were 
community-acquired in 2441 cases; whereas early hospital-acquired and late hospital-acquired cases amounted 
to 1377 and 2687, respectively. Late hospital-acquired BSIs were more frequently observed in male patients and 
the causative microorganisms were more frequently resistant against first line antibiotics (Table 1).
The most common identified microorganism was Escherichia coli (23.2%, 910), followed by S. aureus (18.7%, 
734) and enterococci (13.1%, 515).
The number of microorganisms and possible skin contaminants observed during the study period are shown 
in the Fig. 3. The percentage of possible skin contaminants was low on day zero (29%, n = 473); after which the 
proportion of possible contaminants did not show a significant trend (p for trend = 0.18).
The distribution of microorganisms during the hospitalization is shown in Fig. 4.
We observed an increasing trend for Enterococci from 7.1% on day zero to 28% on day 30 (p < 0.001) and 
for Candida spp. from 0.7 to 11.1% (p < 0.001). E coli decreased from 31.4% on day zero to 16.7% on day 30 
(p < 0.0001) and S. aureus decreased from 19 to 5.6% (p < 0.0001). Klebsiella pneumoniae did not show a signifi-
cant trend (p = 0.41).
Antimicrobial resistance to first-line antibiotics was 13.1% on day zero and then increased continuously to 
more than 60% on days 28–30 (p < 0.001, Fig. 5). Similar trends were observed excluding fungi from the analysis 
(p < 0.001, Supplementary Figure S1). Increasing trends were also observed for resistance to second-line anti-
biotics (p < 0.001).
Discussion
Using a large microbiological database, we analyzed data on 6505 BSI episodes from 35 Swiss ICUs. Data in the 
literature on hospitalization duration and distribution of pathogens are scant. To our knowledge, only the EPIC 
I study showed rates of selected pathogens in the ICU setting depending on the number of hospital days before 
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the study  day4. However, this study (1) did not analyze data relative to the entire hospitalization and (2) did 
not specifically address this research question. We showed that the proportion of enterococcal BSI and resistant 
microorganisms against first- and second-line antibiotics increased substantially during the hospitalization. 
Moreover, we observed that possible contaminants showed the lowest proportion at hospital admission (i.e., day 
zero) but for the remainder of the hospitalization their proportions did not change.
Interestingly, we observed that the proportion of Enterococci increased during the hospitalization and 
accounted for almost 30% of all BSIs in late hospitalizations. It is conceivable that the exposure to antibiotics 
including the increasing use of cephalosporins in  Switzerland11, the accumulation of complications and the 
often increasing case-severity during the hospitalization may predispose patients to develop enterococcal BSI. 
Although we did not investigate individual clinical patient data, our results may help clinicians in selecting 
empirical therapies for patients with long hospitalization duration.
Similarly, we observed that resistance against first or second line antibiotics increased linearly during the 
hospitalization. Clinicians and intensivists often apply a specific cut-off for assessing the acquisition of BSIs (i.e., 
community versus hospital-acquired). These cut-offs frequently guided the selection of antimicrobial therapies. 
For Gram-negative bacteremias, several authors selected a time cut-off of 5 days for comparisons between early 
Figure 1.  Flowchart of ICU-BSI included.
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and late onset following hospital  admission12. In light of our results, simplistic recommendations based on a 
single time cut-off may not properly reflect the complex ICU-acquired BSI epidemiology. Therefore, regarding 
selection of empirical antibiotic therapy, an oversimplified “community” versus “hospital-acquired” classification 
based on duration of hospitalization should be discouraged.
Possible skin contaminants were low on the first day and then remained stable. This may be explained by 
a higher skill level in emergency medicine personnel (versus those on wards) when drawing blood  cultures13. 
Another explanation for the higher proportion of possible contaminants during ICU stays (i.e., excluding the day 
zero) may be the collection of blood through intravascular catheters, which are more prone to  contamination14,15. 
Trends of possible contaminants should be interpreted with caution: we did not perform a patient-based assess-
ment for possible contamination and possible contaminants should not be considered as proven blood culture 
contaminations.
Our study has several limitations. First, we performed an analysis of a microbiological database and clinical 
data were unavailable to us (e.g., baseline comorbidities, reasons for admission, ICU admission date and reason, 
source of BSI and antibiotic treatment) and recommendations on BSI management could not be derived from 
this database. Second, Switzerland is a low-prevalence country regarding multidrug-resistant microorganisms 
Figure 2.  Swiss hospitals included in the study. The disk sizes are proportional to the hospitals’ annual patient 
days. The map was generated with R Version 3.5.2 and the raster package: https:// cran.r- proje ct. org/ web/ packa 
ges/ raster/ index. html.
Table 1.  Characteristics of BSI stratified by acquisition. Community acquired: 0–2 days after hospital 
admission. Early hospital-acquired: 2–5 days after the hospitalization. Late hospital-acquired: > 5 days after the 






(n = 2687) p value
Age ≥ 60 years, n (%) 1729 (70.8) 932 (67.7) 1827 (68) 0.04
Male sex, n (%) 1511 (61.9) 962 (69.9) 1896 (70.6) < 0.01
Hospital type, non-university 
hospital, n (%) 1594 (65.3) 951 (69.1) 1741 (64.8) 0.02
Year 2012–2017 (versus 
2008–2011), n (%) 1146 (46.9) 744 (54) 1337 (49.8) < 0.01
First line resistance (versus 
susceptible) 565 (23.1) 523 (38) 1530 (56.9) < 0.01
Second line resistance (versus 
susceptible)a 37 (1.5) 28 (2.1) 112 (4.3) < 0.01
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Figure 3.  Number and proportion of microorganisms and possible skin contaminants relative to the 
hospitalization duration. Microorganisms included bacteria and fungi.
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and our data cannot be easily generalized to other countries. Third, we defined fungemic BSI episodes as resist-
ant to first class antibiotics: formally, the epidemiology of fungemia cannot be equated with the epidemiology of 
bacteremia. However, we performed a sensitivity analysis excluding fungi which showed similar trends. Fourth, 
we performed simple descriptive analyses without adjustment for other confounders; moreover, we did not 
provide a more sophisticated risk prediction analysis and related score. Fifth, a selection bias could have been 
introduced when restricting the analysis to BSI with known acquisition relative to hospitalization duration. 
Finally, the raw number of ICU-BSI episodes decreased during the hospitalization and, therefore proportional 
trends should be interpreted with caution.
Conclusions
Using data from a large national microbiological database we describe pathogen distribution and bacterial 
resistance in ICU-BSI during hospitalization. The proportion of enterococcal BSI, candidemia and resistant 
microorganisms against first and second line antibiotics increased during hospitalization.
Ethics approval. As the analysis was performed on anonymized non-genetic surveillance data, ethical con-
sent was not required according to the Swiss law for research on humans.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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